149 research outputs found
Non-stationary temporal characterization of the temperature profile of a soil exposed to frost in south-eastern Canada
The objective of this work was to compare time and frequency fluctuations of air and soil temperatures (2-, 5-, 10-, 20- and 50-cm below the soil surface) using the continuous wavelet transform, with a particular emphasis on the daily cycle. The analysis of wavelet power spectra and cross power spectra provided detailed non-stationary accounts with respect to frequencies (or periods) and to time of the structure of the data and also of the relationships that exist between time series. For this particular application to the temperature profile of a soil exposed to frost, both the air temperature and the 2-cm depth soil temperature time series exhibited a dominant power peak at 1-d periodicity, prominent from spring to autumn. This feature was gradually damped as it propagated deeper into the soil and was weak for the 20-cm depth. Influence of the incoming solar radiation was also revealed in the wavelet power spectra analysis by a weaker intensity of the 1-d peak. The principal divergence between air and soil temperatures, besides damping, occurred in winter from the latent heat release associated to the freezing of the soil water and the insulation effect of snowpack that cease the dependence of the soil temperature to the air temperature. Attenuation and phase-shifting of the 1-d periodicity could be quantified through scale-averaged power spectra and time-lag estimations. Air temperature variance was only partly transferred to the 2-cm soil temperature time series and much less so to the 20-cm soil depth
Swedish snuff and incidence of cardiovascular disease. A population-based cohort study
<p>Abstract</p> <p>Background</p> <p>The relationship between smoking and an increased incidence of cardiovascular diseases is well known. Whether smokeless tobacco (snuff) is related to myocardial infarction (MI) or stroke is still controversial. Aim of this study was to explore whether snuff users have an increased incidence of MI or stroke.</p> <p>Methods</p> <p>A total of 16 754 women and 10 473 men (aged 45–73 years), without history of cardiovascular disease (CVD), belonging to the population-based "Malmö Diet and Cancer" study were examined. Incidence of MI and stroke were monitored over 10.3 years.</p> <p>Results</p> <p>Snuff was used by 737 (7.0%) men and 75 (0.4%) women, respectively. Among men, snuff was significantly associated with low occupation level, single civil status, high BMI and with current and former smoking. In women, snuff was associated with lower systolic blood pressure. A total of 964 individuals (3.5%), i.e.544 men (5.3%) and 420 (2.5%) women suffered a MI during the follow-up period. The corresponding numbers of incident stroke cases were 1048, i.e. 553 men (5.3%) and 495 (3.0%) women, respectively. Snuff was not associated with any statistically significant increased risk of MI or stroke in men or women. The relative risks (RR) in male snuff users compared to non-users were 1.05 (95% confidence interval (CI): 0.8–1.4, p = 0.740) for incident MI and 0.97 (0.7–1.4, p = 0.878) for stroke, after taking age and potential confounders into account. In women none of the 420 (2.5%) women who were snuff users had a MI and only one suffered a stroke during the follow-up.</p> <p>Conclusion</p> <p>Several life-style risk factors were more prevalent in snuff-users than in non-users. However, the present study does not support any relationship between snuff and incidence of cardiovascular disease in men.</p
Communication Research
Contains reports on seven research projects.Rockefeller FoundationCarnegie Foundatio
Communication Research
Contains reports on nine research projects.Bell Telephone Laboratories, Incorporate
Use of Flash Glucose-Sensing Technology for 12Â months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes
Introduction: Published evaluations of sensor glucose monitoring use in insulin treated type 2 diabetes are limited. The aim of this study was to assess the impact of flash glucose-sensing technology as a replacement for self-monitoring of blood glucose (SMBG) over a 12-month period in participants with type 2 diabetes who were on intensive insulin therapy. Methods: An open-label, randomized, controlled study in adults with type 2 diabetes on intensive insulin therapy from 26 European diabetes centers aimed at assessing flash glucose sensing technology was conducted. Participants (N = 224) were randomized (1:2 respectively) to a control group (n = 75) that used SMBG (FreeStyle Lite™) or to an intervention group (n = 149) which used sensor glucose data (FreeStyle Libre™ Flash Glucose Monitoring System) for self-management over 6 months. All intervention group participants who completed the 6-month treatment phase continued into an additional 6-month open-access phase. Results: A total of 139 intervention participants completed the 6-month treatment phase and continued into the open-access phase. At 12 months (end of open-access period), time in hypoglycemia [sensor glucose <3.9 mmol/L (70 mg/dL)] was reduced by 50% compared to baseline [−0.70 ± 1.85/24 h (mean ± standard deviation); p = 0.0002]. Nocturnal hypoglycemia [2300 to 0600 hours, <3.9 mmol/L (70 mg/dL)] was reduced by 52%; p = 0.0002. There was no change in time in range [sensor glucose 3.9–10.0 mmol/L (70–180 mg/dL)]. SMBG testing fell from a mean of 3.9 (median 3.9) times/day at baseline to 0.2 (0.0), with an average frequency of sensor scanning of 7.1 (5.7) times/day at 12 months, and mean sensor utilization was 83.6 ± 13.8% (median 88.3%) during the open-access phase. During this 6-month extension period no device-related serious adverse events were reported. Nine participants reported 16 instances of device-related adverse events (e.g. infection, allergy) and 28 participants (20.1%) experienced 134 occurrences of anticipated skin symptoms/sensor-insertion events expected with device use (e.g. erythema, itching and rash). Conclusion: The use of flash glucose-sensing technology for glycemic management in individuals with type 2 diabetes treated by intensive insulin therapy over 12 months was associated with a sustained reduction in hypoglycemia and safely and effectively replaced SMBG. Trial Registration: ClinicalTrials.gov identifier, NCT02082184
- …